The CINSARC signature: Prognostic and predictive of response to chemotherapy?

Cell Cycle

Volumn 9, Issue 19, 2010, Pages 4025-4027

  Bertucci, François ^a,b,c   Finetti, Pascal ^a   Sabatier, Renaud ^a   Birnbaum, Daniel ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b IPC   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Cell cycle; Chemotherapy; Expression profiling; Prognosis; Soft tissue sarcoma

Indexed keywords

ANTHRACYCLINE; IFOSFAMIDE; KINESIN; POLO LIKE KINASE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CELL CYCLE PHASE; CELL CYCLE PROGRESSION; CENTROMERE; CENTROSOME; CHEMOTHERAPY; CHROMOSOMAL INSTABILITY; CYTOKINESIS; DISEASE COURSE; DNA REPAIR; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC CODE; HISTOPATHOLOGY; HUMAN; LETTER; MASTECTOMY; OVERALL SURVIVAL; PHENOTYPE; PROGNOSIS; SOFT TISSUE SARCOMA; TREATMENT RESPONSE;

EID: 77958481191     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.19.13463     Document Type: Letter

References (15)

1. Pervaiz N, et al. Cancer 2008; 113:573-81.
2. Bertucci F, et al. Lancet Oncol 2001; 2:674-82.
3. Nielsen TO, et al. J Clin Oncol 2010; 28:1796-805.
4. Chibon F, et al. Nat Med 2010; 16:781-7.
5. Sotiriou C, et al. Nat Rev Cancer 2007; 7:545-53.
6. Holland AJ, et al. Cell Cycle 2010; 9:2731-6.
7. Desmedt C, et al. Cell Cycle 2006; 5:2198-202.
8. Finetti P, et al. Cancer Res 2008; 68:767-76.
9. Sotiriou C, et al. J Natl Cancer Inst 2006; 98:262-72.
10. Hess KR, et al. J Clin Oncol 2006; 24:4236-44.
11. Miglarese MR, et al. Expert Opin Investig Drugs 2006; 15:1411-25.
12. Schwartz GK, et al. J Clin Oncol 2005; 23:9408-21.
13. Strebhardt K. Nat Rev Drug Discov 2010; 9:643-60.
14. Boss DS, et al. Oncologist 2009; 14:780-93.
15. de Carcer G, et al. Curr Med Chem 2007; 14:969-85.